Last week, readers were most interested in a story about a proposed acquisition by Abbott of Exact Sciences that would launch Abbott into the cancer testing space.

PrognomiQ announced the initial launch of its ProVue blood test while Mercy presented new data detailing the performance of its Halo lung cancer test.

The firm's new strategy revolves around adding to its test menu in an impactful way and expanding its installed base of instruments.

NEW YORK – French precision psychiatry firm Alcediag is planning a European commercialization strategy for its test to differentiate between depression and bipolar disorder after launching in France, ...

NEW YORK – Abbott Laboratories announced Thursday that it will acquire cancer diagnostic firm Exact Sciences for an estimated enterprise value of $23 billion. Abbott will acquire all outstanding ...

A slew of new studies and reports suggest that new molecular approaches may soon help reduce the global burden of tuberculosis.

"Including bacterial isolates in our FDA studies was a strategic decision — it provides hospital laboratories with flexibility and ensures that QuickMIC integrates seamlessly into existing ...

With the transaction, which Bloomberg News said could be announced within the next several days, Abbott would acquire tests including Exact's Cologuard, among other tests.

The test, which runs on the BD Viper LT and BD Cor automated PCR systems, will be added to the WHO's list of prequalified IVDs for cervical cancer screening.

The company presented data at last week's AMP annual meeting proving the concept of its platform's applications in infectious disease and cancer.